It dived, as 12 investors sold Cara Therapeutics Inc shares while 23 reduced holdings.
BidaskClub cut shares of Cara Therapeutics, Inc. RHO Capital Partners Inc. now owns 3,568,057 shares of the biopharmaceutical company’s stock valued at $65,617,000 after buying an additional 500,000 shares during the period. Parametric Portfolio Associates LLC now owns 98,962 shares of the biopharmaceutical company’s stock worth $1,820,000 after buying an additional 41,237 shares during the last quarter. Jennison Associates LLC purchased a new stake in Cara Therapeutics during the first quarter worth about $5,517,000. Rhumbline Advisers now owns 30,537 shares of the biopharmaceutical company’s stock valued at $470,000 after buying an additional 4,375 shares during the last quarter. Finally, Jennison Associates LLC bought a new position in shares of Cara Therapeutics during the first quarter worth about $5,517,000. Legal & General Group Plc now owns 7,167 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 678 shares during the last quarter. The Massachusetts-based Geode Cap Management Ltd Limited Liability Company has invested 0% in Cara Therapeutics Inc (NASDAQ:CARA). State Street Corp is the second biggest holder with 3 million shares now valued at 49.94 million whilst RHO CAPITAL PARTNERS LLC has 3 million shares valued at 28.50 million. (CARA) opened at 13.07 on Wednesday. The Company has 52-week high of $28.50 and 52-week low of $5.07. The stock’s 50-day moving average price is $16.88 and its 200-day moving average price is $16.34. The company has market cap of $424.87 million. Consol Energy Inc. (CNX) reported that second-quarter net income of $169.5 million, after reporting a loss in the same period a year earlier. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.73) by $0.08.
Looking forward, for the quarter ending Sep-17, 6 analysts have a mean sales target of 0.19 million.
NEOT’s revenue has declined at an average annualized rate of about 0% during the past five years. During the same period previous year, the firm posted ($0.39) EPS. About shares traded. Cara Therapeutics Inc (NASDAQ:CARA) has risen 206.00% since August 2, 2016 and is uptrending.
ILLEGAL ACTIVITY NOTICE: “Baldwin Brothers Inc”. Symons Capital Management Inc owns 381,945 shares or 5.65% of their U.S. portfolio. “(CARA)” was first posted by BNB Daily and is owned by of BNB Daily. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of US and worldwide trademark and copyright laws. (CRIS). Earlier in her career, Dr. Mohindru spent several years as an equity research analyst covering the biotechnology sector at ThinkEquity, LLC, Credit Suisse and UBS.
Stock market analysts watching Cara Therapeutics Inc (CARA) have recently changed their ratings on the stock. Finally, Vetr downgraded shares of Cara Therapeutics from a “strong-buy” rating to a “buy” rating and set a $21.73 target price on the stock.in a research report on Wednesday, June 21st. Scotiabank lifted their price target on Cara Therapeutics from $33.00 to $34.00 and gave the stock an “outperform” rating in a research report on Monday, May 15th.
Cara Therapeutics Inc had its ” rating reiterated by analysts at Piper Jaffray. Russell Investments Group Ltd. now owns 49,910 shares of the biopharmaceutical company’s stock worth $918,000 after buying an additional 6,842 shares in the last quarter. The company presently has a consensus rating of Buy and an average target price of $25.68.
In other news, VP Frederique Ph.D. Menzaghi sold 3,000 shares of the firm’s stock in a transaction dated Friday, July 14th. The stock was sold at an average price of $15.05, for a total value of $376,250.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Derek T. Chalmers sold 25,000 shares of the business’s stock in a transaction on Friday, July 14th. The disclosure for this sale can be found here. Company insiders own 7.70% of the company’s stock.
Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The corporation is focused on developing and commercializing chemical entities created to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that recipient the body’s peripheral nervous system.